EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Changing Landscape of Cancer Immunotherapy and Precision Oncology

Md Abdus Salam, Md Yusuf Al-Amin

TAJ: Journal of Teachers Association · 01.06.2026 · 39 (2) · 231-244

DOI: 10.70818/taj.v39i2.0710 ↗

Kurz gefasst

Fachartikel in der Zeitschrift TAJ: Journal of Teachers Association, online erschienen am 01.06.2026. Verfasst von Md Abdus Salam und 1 weiteren Autor:innen. Die Arbeit nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy is steering personalized cancer care toward mechanism‑driven, biomarker‑guided treatment that adapts over time. Cancer immunotherapy has revolutionized oncology by harnessing three major synergistic strategies. First, checkpoint inhibitors that work primarily by reactivating exhausted T cells, restoring their ability to recognize and attack cancer. Second, CAR-T cell therapies which provide patients with engineered immune effectors that can directly target tumor-associated antigens with precision. Third, oncolytic viruses that trigger localized inflammation within tumors and act as in situ vaccines, reshaping the tumor microenvironment to promote durable immune responses. CAR‑T therapy shows strong, reproducible benefits in hematologic malignancies, while next‑generation designs with logic‑gated circuits are being developed to boost persistence, trafficking, and safety that are especially promising for solid tumors. Moreover, when combined with oncolytic platforms, it enhances tumor penetration and local immune activation. Oncolytic viruses can inflame immunologically “cold” tumors, amplifying local cytokine and chemokine signals to recruit and activate immune cells, which in turn enhances the activity of checkpoint inhibitors and CAR‑T cells. Further, by coupling tumor‑selective lysis with immune activation and microenvironmental reprogramming, oncolytic viruses create an in situ vaccination effect that can broaden and deepen responses to convert non‑responders into responders. This narrative review integrates mechanistic insights and compiles evidence on predictive and dynamic biomarkers like PD‑L1, MSI‑H/dMMR, tumor mutational burden, antigen density, and spatial immune profiling to refine patient selection, and outlines combination and sequencing strategies across all immunotherapy modalities. It also highlights the resistance mechanisms, immune toxicities, and emerging frontiers in cancer immunotherapy.

Zitieren

APA

Salam, M. A., & Al-Amin, M. Y. (2026). The Changing Landscape of Cancer Immunotherapy and Precision Oncology. TAJ: Journal of Teachers Association, 39(2), 231-244. https://doi.org/10.70818/taj.v39i2.0710

Vancouver

Salam MA, Al-Amin MY. The Changing Landscape of Cancer Immunotherapy and Precision Oncology. TAJ: Journal of Teachers Association. 2026;39(2):231-244. doi:10.70818/taj.v39i2.0710

BibTeX
@article{Salam2026,
  author = {Salam, Md Abdus and Al-Amin, Md Yusuf},
  title = {The Changing Landscape of Cancer Immunotherapy and Precision Oncology},
  journal = {TAJ: Journal of Teachers Association},
  year = {2026},
  volume = {39},
  number = {2},
  pages = {231--244},
  doi = {10.70818/taj.v39i2.0710}
}
Kostenlos starten →